These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Cost-effectiveness analysis of ceftriaxone and cefotaxime in the treatment of community-acquired pneumonia]. García-Contreras F, Del-Angel-García G, Ramírez Cuenca A, Malváez-Valdes M, Vega Yáñez A, Amato D. Rev Invest Clin; 2000; 52(4):418-26. PubMed ID: 11061104 [Abstract] [Full Text] [Related]
3. [Cost-effectiveness comparative study of ceftriaxone verus cefotaxime in the treatment of complicated urinary infections]. Martínez Jabaloyas JM, Sanz Chinesta S, Jiménez Cruz JF, Flores Corral N, Unda Urzaiz M, Leiva Galvis O, González Romojaro V, Hernández Fernández C, Lledó García E, Rioja Sanz LA, Gonzalvo Ibarra A, Camacho González JE, Ruíz Alvárez-Cienfuegos F, Resel Estévez L, Corral Saleta J, Burgos Rodríguez R, Del Rosal Samaniego JM. Actas Urol Esp; 1997; 21(7):668-74. PubMed ID: 9412209 [Abstract] [Full Text] [Related]
4. Cefotaxime in the treatment of prophylaxis of surgical infections. Wittmann DH, Jones RN, Malledant J, Privitera G. J Chemother; 1997 May; 9 Suppl 2():19-33. PubMed ID: 9248973 [Abstract] [Full Text] [Related]
8. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. Parrish AG. S Afr Med J; 1998 Sep; 88(9):1046, 1048; author reply 1050-1. PubMed ID: 9798485 [No Abstract] [Full Text] [Related]
11. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review. Bijie H, Kulpradist S, Manalaysay M, Soebandrio A. J Chemother; 2005 Feb; 17(1):3-24. PubMed ID: 15828439 [Abstract] [Full Text] [Related]
13. Retrospective analysis of the clinical and economic outcomes of twice-daily dosing of cefotaxime in a Canadian tertiary care institution. Tin LY, Pitre M, Conly JM. Diagn Microbiol Infect Dis; 1995 Feb; 22(1-2):135-40. PubMed ID: 7587028 [Abstract] [Full Text] [Related]
14. A retrospective analysis of twice-daily cefotaxime compared to conventional therapy for the treatment of infections in a USA hospital. Burke JP, Pestotnik SL, Classen DC, Lloyd JF. Diagn Microbiol Infect Dis; 1995 Feb; 22(1-2):167-9. PubMed ID: 7587034 [Abstract] [Full Text] [Related]
15. Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapy. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D. Int J Antimicrob Agents; 2004 Mar; 23(3):240-6. PubMed ID: 15164964 [Abstract] [Full Text] [Related]
18. Antibiotic treatment for urinary tract infections in pediatric patients. Hellerstein S. Minerva Pediatr; 2003 Oct; 55(5):395-406. PubMed ID: 14608263 [Abstract] [Full Text] [Related]
19. Treatment of Citrobacter koseri infection with ciprofloxacin and cefotaxime in a preterm infant. McPherson C, Gal P, Ransom JL. Ann Pharmacother; 2008 Jul; 42(7):1134-8. PubMed ID: 18577764 [Abstract] [Full Text] [Related]